# Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone

> **NCT00121667** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1462 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Saxagliptin + Metformin
- **DRUG:** Saxagliptin + Metformin
- **DRUG:** Saxagliptin + Metformin
- **DRUG:** Placebo + Metformin
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00121667
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-10
- **Final completion:** 2010-02
- **Target enrollment:** 1462 (ACTUAL)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121667, "Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00121667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*